Physician profile
Thomas Gilliland
NPI 1093196065
$35,400.09
in general payments reported to CMS, 2019-2025
8 companies · $1,103 in 2025
The $1,103 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $531 · 2023: $355 · 2024: $33K · 2025: $1,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $30K · Travel and Lodging: $2,604 · Food and Beverage: $2,264 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $30,000.00 |
| Travel and Lodging | $2,604.36 |
| Food and Beverage | $2,263.54 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $16,269.36 | 2023-2024 | Corevalve Evolut R, Onyx Frontier |
| Boston Scientific Corporation | $15,372.44 | 2022-2024 | |
| Edwards Lifesciences Corporation | $2,802.84 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal |
| Abbott Laboratories | $578.76 | 2023-2025 | Mitraclip, Navitor, Triclip |
| Cardiovascular Systems INC. | $158.75 | 2022 | |
| International Life Sciences | $108.23 | 2023 | |
| Cathworks, INC. | $84.12 | 2023 | Ffrangio |
| Abiomed | $25.59 | 2023 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Gilliland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.